View Older Stories View More Recent Stories

Jun 5, 2017 07:08AM Merck (MRK) Presents New Data From Phase 2 I-SPY 2 TRIAL Shows Improved Outcomes with Combination of KEYTRUDA (pembrolizumab) Plus Standard Neoadjuvant Therapy
Jun 5, 2017 07:05AM Incyte (INCY), Merck (MRK) Provide Updated Data from ECHO-202 Trial of Epacadostat in Combination with KEYTRUDA
Jun 5, 2017 07:05AM New Data From Phase 2 I-SPY 2 TRIAL Shows Improved Outcomes with Combination of Merck’s KEYTRUDA® (pembrolizumab) Plus Standard Neoadjuvant Therapy in Patients with High-Risk Breast Cancer
Jun 5, 2017 07:00AM Updated Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with Merck’s KEYTRUDA® (Pembrolizumab) Demonstrate Clinical Activity across Multiple Tumor Types
Jun 5, 2017 06:43AM Merck (MRK) Reports 1+ Year Follow-Up on KEYTRUDA (pembrolizumab) Shows Continued Overall Survival Benefit Over Chemotherapy
Jun 5, 2017 06:41AM Merck (MRK) Announces New Monotherapy Data for KEYTRUDA (pembrolizumab) in Heavily Pre-Treated Patients with Advanced Gastric Cancer
Jun 5, 2017 05:48AM Merck (MRK) Reports New Data on Response for Merck’s KEYTRUDA (pembrolizumab) in Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors
Jun 5, 2017 05:46AM Merck (MRK) Announces Follow-Up Data with Merck’s KEYTRUDA (pembrolizumab) in Combination with Pemetrexed & Carboplatin at ASCO Meetings
Jun 4, 2017 10:00AM New Monotherapy Data for Merck’s KEYTRUDA® (pembrolizumab) in Heavily Pre-Treated Patients with Advanced Gastric Cancer to be Presented at 2017 ASCO Annual Meeting
Jun 4, 2017 09:00AM With More than One-Year Follow-Up, Merck’s KEYTRUDA® (pembrolizumab) Shows Continued Overall Survival Benefit Over Chemotherapy as Second-Line Treatment for Advanced Urothelial Carcinoma Patients P
Jun 3, 2017 09:00AM Combination of Incyte’s Epacadostat plus Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Activity in Clinical Trial of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Jun 3, 2017 08:30AM New Data Show Durability of Response for Merck’s KEYTRUDA® (pembrolizumab) in Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors, Regardless of Tumor
Jun 3, 2017 08:00AM Longer Term Follow-Up Data with Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Carboplatin in First-Line Nonsquamous Metastatic Non-Small Cell Lung Cancer (NSCLC) to Be Presen
Jun 2, 2017 07:35AM Merck (MRK) Announces Updated Longer-Term Overall Survival Data from KEYNOTE-006 Phase 3 Study of KEYTRUDA at ASCO
Jun 2, 2017 07:30AM With Nearly Three Years of Follow-Up, KEYTRUDA® (pembrolizumab) Data Demonstrated Improved Survival Benefit Compared to Ipilimumab in Advanced Melanoma
Jun 1, 2017 08:00AM Merck to Present at the Bernstein’s 33rd Annual Strategic Decisions Conference
May 30, 2017 08:00AM Merck Highlights Ongoing Commitment to Fighting Infectious Diseases With More than 20 Data Presentations at ASM Microbe 2017
May 30, 2017 07:04AM Merck (MRK) Announces FDA Approval of ISENTRESS HD Combo for Treatment of HIV-1 Infection
May 30, 2017 07:00AM Merck Receives FDA Approval of ISENTRESS® HD (raltegravir), a New Once-Daily Option, in Combination with Other Antiretroviral Agents, for the Treatment of HIV-1 Infection in Appropriate Patients
May 25, 2017 08:01AM Merck (MRK) Enters License Agreement with Teijin Pharma
May 25, 2017 08:00AM Merck Enters Exclusive Worldwide License Agreement with Teijin Pharma for Investigational Antibody Candidate Targeting Tau
May 23, 2017 04:36PM Merck (MRK) Granted FDA Approval of KEYTRUDA (pembrolizumab) for Adult & Pediatric Patients with Unresectable or Metastatic, Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient Cancer
May 23, 2017 04:34PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Adult and Pediatric Patients with Unresectable or Metastatic, Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient Cancer
May 23, 2017 01:19PM Merck Announces Third-Quarter 2017 Dividend
May 23, 2017 06:57AM Merck's (MRK) sBLA for KEYTRUDA to Treat Recurrent or Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Granted FDA Priority Review
May 23, 2017 06:55AM FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) for Treatment of Recurrent or Advanced Gastric or Gastroesophageal Junction Ade
May 22, 2017 11:21AM Merck (MRK) Announces Presentation of Phase 2 Results for MK-7264
May 22, 2017 11:20AM Merck Announces Presentation of Phase 2 Results for MK-7264, an Investigational, P2X3 Receptor Antagonist, Being Evaluated for the Treatment of Chronic Cough
May 19, 2017 08:01AM Merck (MRK) Announces CHMP Opinion Recommending Approval of ISENTRESS 600 mg
May 19, 2017 08:00AM Merck Receives CHMP Positive Opinion Recommending Approval of ISENTRESS® (raltegravir) 600 mg in the European Union
May 19, 2017 04:00AM 100 Healthy Years - Are Kids Prepared?
May 18, 2017 04:01PM Merck (MRK) Says FDA Approves KEYTRUDA for Two New Indications fo Types of Bladder Cancer
May 18, 2017 04:00PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer
May 17, 2017 05:21PM Merck (MRK) Says Data for KEYTRUDA Across 16 Types of Cancer to Be Presented at ASCO
May 17, 2017 05:00PM Data for KEYTRUDA® (pembrolizumab) Across 16 Types of Cancer from Merck’s Industry-Leading Immuno-Oncology Program to Be Presented at the 2017 ASCO Annual Meeting
May 17, 2017 05:00PM Merck KGaA, Darmstadt, Germany, and Pfizer to Present Data Highlighting Potential of Avelumab in Challenging Cancers at ASCO 2017
May 16, 2017 08:02AM Merck (MRK) to Report New Phase 3 Data on Investigational Ertugliflozin, Additional Analyses of Studies of JANUVIA® (sitagliptin) & Real-World Evidence Research at ADA Meetings
May 16, 2017 08:00AM Merck to Present New Phase 3 Data on Investigational Ertugliflozin, Additional Analyses of Studies of JANUVIA® (sitagliptin), and Real-World Evidence Research at the 77th Scientific Sessions of the A
May 10, 2017 05:40PM Merck (MRK) Announces FDA Approval for KEYTRUDA as First-Line Combination Therapy with Pemetrexed and Carboplatin for Patients with Metastatic NSCLC
May 10, 2017 05:39PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as First-Line Combination Therapy with Pemetrexed and Carboplatin for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC), Irrespe
May 9, 2017 03:56PM Merck KGaA, Pfizer (PFE) Announce FDA Approval for BAVENCIO for Common Type of Advanced Bladder Cancer
May 9, 2017 03:53PM FDA Grants BAVENCIO® (avelumab) Approval for a Common Type of Advanced Bladder Cancer
May 5, 2017 07:05AM Merck (MRK) Announces EC Approval of KEYTRUDA for Patients with Relapsed/Refractory cHL
May 5, 2017 07:00AM European Commission Approves KEYTRUDA® (pembrolizumab) for Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Who Failed Autologous Stem Cell Transplant and Brentuximab Vedotin (BV), or
May 3, 2017 08:00AM Merck to Present at the Deutsche Bank 42nd Annual Health Care Conference
May 2, 2017 06:45AM Merck Announces First-Quarter 2017 Financial Results
Apr 25, 2017 08:00AM America's Diabetes Challenge Unveils Common Challenges Affecting the Type 2 Diabetes Community
Apr 24, 2017 05:40AM Merck (MRK) Reports New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C
Apr 22, 2017 07:00AM Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C
Apr 21, 2017 10:00AM Real-World Observational Study in the U.S. Veterans Affairs System Evaluating Use of Merck’s ZEPATIER® (Elbasvir and Grazoprevir) Shows High Sustained Virologic Response Rates in Patients with Chro
View More Recent Stories View Older Stories